Avalo Therapeutics (AVTX) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Avalo Therapeutics (NASDAQ: AVTX):

• 10/26/2026 – Avalo Therapeutics was given a new $16.00 price target by Oppenheimer.
• 10/26/2026 – Avalo Therapeutics had its “outperform” rating reaffirmed by Oppenheimer.
• 10/23/2026 – Avalo Therapeutics had its price target lowered by Wedbush from $34.00 to $22.00. They now have an “outperform” rating on the stock.
• 10/23/2026 – Avalo Therapeutics had its price target lowered by BTIG Research to $10.00. They now have a “buy” rating on the stock.
• 10/23/2026 – Avalo Therapeutics was downgraded by Guggenheim from “buy” to “neutral”.
• 10/23/2026 – Avalo Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”.
• 10/16/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/16/2026 – Avalo Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/12/2026 – Avalo Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the sale, the chief financial officer owned 39,900 shares in the company, valued at approximately $651,567. The trade was a 23.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 23,258 shares of company stock valued at $395,434. 4.46% of the stock is currently owned by company insiders.

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.